WallStSmart

Biora Therapeutics Inc (BIOR)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Biora Therapeutics Inc generates 16% more annual revenue ($860,000 vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. BIOR earns a higher WallStSmart Score of 38/100 (F).

BIOR

Hold

38

out of 100

Grade: F

Growth: 5.3Profit: 3.5Value: 6.7Quality: 4.5
Piotroski: 2/9Altman Z: -56.45

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIOR3 strengths · Avg: 10.0/10
P/E RatioValuation
0.6x10/10

Attractively priced relative to earnings

Revenue GrowthGrowth
15800.0%10/10

Revenue surging 15800.0% year-over-year

Debt/EquityHealth
-0.3710/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

BIOR4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$994,9903/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BIOR

The strongest argument for BIOR centers on P/E Ratio, Revenue Growth, Debt/Equity. Revenue growth of 15800.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : BIOR

The primary concerns for BIOR are EPS Growth, Market Cap, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

BIOR profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

BIOR is growing revenue faster at 15800.0% — sustainability is the question.

BIOR generates stronger free cash flow (-9M), providing more financial flexibility.

Bottom Line

BIOR scores higher overall (38/100 vs 24/100) and 15800.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Biora Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Biora Therapeutics, Inc., a biotechnology company, is engaged in the development of oral biotherapeutic products. The company is headquartered in San Diego, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?